Cargando…

Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers

OBJECTIVE: The aim of the present study is to evaluate the efficacy, complications, and contributing factors of immunosuppressive therapy (IST) response in children with acquired aplastic anemia (AA) and to explore optimal therapeutic methods for different clinical AA types. METHODS: A total of 130...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Junbin, Huang, Lifen, Liu, Su, Lin, Shaofen, Cheng, Yucai, Jiang, Xiaoyun, Xue, Hongman, Li, Chikong, Chen, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259937/
https://www.ncbi.nlm.nih.gov/pubmed/34239322
http://dx.doi.org/10.2147/IJGM.S313898
_version_ 1783718737616044032
author Huang, Junbin
Huang, Lifen
Liu, Su
Lin, Shaofen
Cheng, Yucai
Jiang, Xiaoyun
Xue, Hongman
Li, Chikong
Chen, Chun
author_facet Huang, Junbin
Huang, Lifen
Liu, Su
Lin, Shaofen
Cheng, Yucai
Jiang, Xiaoyun
Xue, Hongman
Li, Chikong
Chen, Chun
author_sort Huang, Junbin
collection PubMed
description OBJECTIVE: The aim of the present study is to evaluate the efficacy, complications, and contributing factors of immunosuppressive therapy (IST) response in children with acquired aplastic anemia (AA) and to explore optimal therapeutic methods for different clinical AA types. METHODS: A total of 130 children diagnosed with acquired AA underwent IST in the Department of Pediatrics at Sun Yat-sen Memorial Hospital and the Department of Pediatrics at Seventh Affiliated Hospital, Sun Yat-sen University, between January 1, 2006, and July 15, 2020. The overall survival (OS), response rates, complications, and response predictors were analyzed. The response rates were compared according to clinical AA type. RESULTS: All 130 children with AA were followed up with for a median of 50.6 months. Among the patients, 25 had non-severe AA (NSAA), 64 had severe AA (SAA), and 41 had very severe AA (VSAA). All patients initially received IST. In 13 patients, the IST failed; these patients received an allo-hematopoietic stem cell transplant as a salvage regimen. The OS rate was 90.3% ± 2.8%, and the response rates at 3, 6, 9, and 12 months were 34.19%, 39.32%, 49.57%, and 66.67%, respectively. The prolonged follow-up period might have led to higher response rates, especially in patients with SAA and VSAA. A multivariate logistic regression analysis of prognostic factors was conducted; the results showed that high red blood cell (RBC) and platelet (PLT) counts were associated with a high overall response rate and that the RBC count at diagnosis is a major contributing factor. CONCLUSION: With the use of rabbit anti-thymocyte globulin, proper cyclosporine management, and a prolonged IST follow-up period, a higher number of patients with acquired AA than normal achieved response. Proportionally, the number of patients who achieved remission within 12 months was higher in the SAA group (38.18%→63.64%) and VSAA group (28.95%→65.79%) than in the NSAA group (58.33%→75%). Higher RBC and PLT counts at diagnosis can predict a favorable outcome.
format Online
Article
Text
id pubmed-8259937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82599372021-07-07 Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers Huang, Junbin Huang, Lifen Liu, Su Lin, Shaofen Cheng, Yucai Jiang, Xiaoyun Xue, Hongman Li, Chikong Chen, Chun Int J Gen Med Original Research OBJECTIVE: The aim of the present study is to evaluate the efficacy, complications, and contributing factors of immunosuppressive therapy (IST) response in children with acquired aplastic anemia (AA) and to explore optimal therapeutic methods for different clinical AA types. METHODS: A total of 130 children diagnosed with acquired AA underwent IST in the Department of Pediatrics at Sun Yat-sen Memorial Hospital and the Department of Pediatrics at Seventh Affiliated Hospital, Sun Yat-sen University, between January 1, 2006, and July 15, 2020. The overall survival (OS), response rates, complications, and response predictors were analyzed. The response rates were compared according to clinical AA type. RESULTS: All 130 children with AA were followed up with for a median of 50.6 months. Among the patients, 25 had non-severe AA (NSAA), 64 had severe AA (SAA), and 41 had very severe AA (VSAA). All patients initially received IST. In 13 patients, the IST failed; these patients received an allo-hematopoietic stem cell transplant as a salvage regimen. The OS rate was 90.3% ± 2.8%, and the response rates at 3, 6, 9, and 12 months were 34.19%, 39.32%, 49.57%, and 66.67%, respectively. The prolonged follow-up period might have led to higher response rates, especially in patients with SAA and VSAA. A multivariate logistic regression analysis of prognostic factors was conducted; the results showed that high red blood cell (RBC) and platelet (PLT) counts were associated with a high overall response rate and that the RBC count at diagnosis is a major contributing factor. CONCLUSION: With the use of rabbit anti-thymocyte globulin, proper cyclosporine management, and a prolonged IST follow-up period, a higher number of patients with acquired AA than normal achieved response. Proportionally, the number of patients who achieved remission within 12 months was higher in the SAA group (38.18%→63.64%) and VSAA group (28.95%→65.79%) than in the NSAA group (58.33%→75%). Higher RBC and PLT counts at diagnosis can predict a favorable outcome. Dove 2021-07-02 /pmc/articles/PMC8259937/ /pubmed/34239322 http://dx.doi.org/10.2147/IJGM.S313898 Text en © 2021 Huang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Huang, Junbin
Huang, Lifen
Liu, Su
Lin, Shaofen
Cheng, Yucai
Jiang, Xiaoyun
Xue, Hongman
Li, Chikong
Chen, Chun
Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
title Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
title_full Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
title_fullStr Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
title_full_unstemmed Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
title_short Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers
title_sort clinical outcome of acquired post-immunosuppressive-therapy aplastic anemia in pediatric patients: a 13-year experience in two southern china tertiary care centers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259937/
https://www.ncbi.nlm.nih.gov/pubmed/34239322
http://dx.doi.org/10.2147/IJGM.S313898
work_keys_str_mv AT huangjunbin clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT huanglifen clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT liusu clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT linshaofen clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT chengyucai clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT jiangxiaoyun clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT xuehongman clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT lichikong clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters
AT chenchun clinicaloutcomeofacquiredpostimmunosuppressivetherapyaplasticanemiainpediatricpatientsa13yearexperienceintwosouthernchinatertiarycarecenters